)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Herantis Pharma
Herantis Pharma (HRNTS) investor relations material
Herantis Pharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary20 Aug, 2026
Executive summary
HER-096 is advancing to a phase II trial as a potential first disease-modifying therapy for Parkinson's, supported by strong phase I/1b safety, biomarker, and translational data in both patients and healthy volunteers.
The phase II trial will be a randomized, placebo-controlled, double-blind study in early-stage Parkinson's, leveraging digital monitoring and biomarkers to assess efficacy.
HER-096 leverages CDNF biology for a broad, multimodal mechanism of action with neurorestorative potential, addressing a major unmet need in Parkinson's where no disease-modifying therapies exist.
The company operates in a large and growing market with high unmet need, as current therapies only address symptoms and lose effectiveness over time.
Positive FDA feedback, new leadership appointments, and collaborations for digital biomarker integration and CRO support have strengthened operational readiness.
Financial highlights
Operating expenses and cost base remained flat year-over-year, with spending focused on phase II preparations, biomarker development, and investor relations.
Net loss for 1H 2026 was EUR 3.3 million, compared to EUR 3.2 million in 1H 2025.
Cash and securities at June 30, 2026, ranged from EUR 3.5 million to EUR 4.6 million, with equity at EUR -0.7 million.
Long-term debt increased to EUR 3.4 million due to additional research and foundation funding.
EUR 4.2 million raised via share issue and EUR 8.0 million Horizon Europe grant secured for phase II trial.
Outlook and guidance
Clinical trial application for phase II is expected by year-end 2026, with first patient enrollment in 1H 2027 and interim efficacy data in 1H 2029.
Cash runway extends until end of 1H 2027, but additional capital is required to launch and complete the phase II trial.
R&D expenses and cash burn are expected to increase as phase II activities ramp up.
Active discussions are ongoing with potential pharma partners and investors for additional funding and development partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Herantis Pharma
- HER-096 advances as a first-in-class disease-modifying Parkinson's therapy with strong support.HRNTS
Company presentation - Phase II-A trial for HER-096 in Parkinson's uses digital endpoints, FDA-backed, and is well-funded.HRNTSStudy update
- HER-096 met all Phase 1b endpoints; Phase 2 readiness depends on securing further funding.HRNTSH2 2025
- HER-096 advances as a Phase 2-ready, first-in-class disease-modifying therapy for Parkinson's.HRNTSCompany presentation
- HER-096 shows robust, dose-dependent biomarker evidence of target engagement in Parkinson's.HRNTSStudy Result
- HER-096 Phase 1b completed; topline data and Phase 2 depend on new funding and partnerships.HRNTSH1 2025
- HER-096 advances in clinical trials for Parkinson's, backed by strong safety data and major funding.HRNTSR&D Day 2024
- HER-096 advances to Phase 1b with strong funding, but Phase II will require more capital.HRNTSH1 2024
- HER-096 advances in clinical trials with robust funding and a cash runway into Q2 2026.HRNTSH2 2024
Next Herantis Pharma earnings date
H2 20265 Mar, 2027
Herantis Pharma
Next Herantis Pharma earnings date
H2 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Herantis Pharma Oyj is a Finnish biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. The company's lead program centers around HER-096, a small synthetic chemical designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF). This treatment aims to address the progression of Parkinson's by protecting neurons and enhancing their function. The company is headquartered in Espoo, Finland, and its shares are listed on the Helsinki Stock Exchange.